Cargando…

Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?

Intense efforts have been made by both industry and academia over the last three decades to produce viable hemoglobin (Hb)-based oxygen carriers (HBOCs), also known as “blood substitutes”. Human trials conducted so far by several manufactures in a variety of clinical indications, including trauma, a...

Descripción completa

Detalles Bibliográficos
Autor principal: Alayash, Abdu I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372714/
https://www.ncbi.nlm.nih.gov/pubmed/28054978
http://dx.doi.org/10.3390/biom7010002

Ejemplares similares